186 related articles for article (PubMed ID: 21593568)
1. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics.
Zimmermann R; Lelental N; Ganslandt O; Maler JM; Kornhuber J; Lewczuk P
J Alzheimers Dis; 2011; 25(4):739-45. PubMed ID: 21593568
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Preanalytical Cerebrospinal Fluid Handling and Storage Factors on Measurement of Aβ1-42, Aβ1-40, and pTau181 Using an Automated Chemiluminescent Platform.
Ho S; Darrow J; De Simone F; Calabro A; Gannon S; Esquivel R; Thakker P; Khingelova K; Rao A; Zhang Y; Moghekar A
J Appl Lab Med; 2024 Jul; 9(4):789-802. PubMed ID: 38712812
[TBL] [Abstract][Full Text] [Related]
3. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42).
Kaiser E; Schönknecht P; Thomann PA; Hunt A; Schröder J
Neurosci Lett; 2007 May; 417(2):193-5. PubMed ID: 17408854
[TBL] [Abstract][Full Text] [Related]
4. Bacterial contamination and the transport vial material affect cerebrospinal fluid concentrations of β-Amyloid and Tau protein as determined by enzyme immunoassay.
Fronek K; Lange P; Spreer A; Eiffert H; Nau R
Dement Geriatr Cogn Disord; 2011; 32(2):126-34. PubMed ID: 21952521
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.
Lelental N; Brandner S; Kofanova O; Blennow K; Zetterberg H; Andreasson U; Engelborghs S; Mroczko B; Gabryelewicz T; Teunissen C; Mollenhauer B; Parnetti L; Chiasserini D; Molinuevo JL; Perret-Liaudet A; Verbeek MM; Andreasen N; Brosseron F; Bahl JM; Herukka SK; Hausner L; Frölich L; Labonte A; Poirier J; Miller AM; Zilka N; Kovacech B; Urbani A; Suardi S; Oliveira C; Baldeiras I; Dubois B; Rot U; Lehmann S; Skinningsrud A; Betsou F; Wiltfang J; Gkatzima O; Winblad B; Buchfelder M; Kornhuber J; Lewczuk P
J Alzheimers Dis; 2016 Mar; 52(1):51-64. PubMed ID: 26967210
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal IgG synthesis in patients with alterations in the neurochemical dementia diagnostics.
Zimmermann R; Beck G; Knispel S; Maler JM; Weih M; Wiltfang J; Kornhuber J; Lewczuk P
J Alzheimers Dis; 2010; 19(4):1199-203. PubMed ID: 20308786
[TBL] [Abstract][Full Text] [Related]
7. Pre-analytical factors influencing the stability of cerebrospinal fluid proteins.
Simonsen AH; Bahl JM; Danborg PB; Lindstrom V; Larsen SO; Grubb A; Heegaard NH; Waldemar G
J Neurosci Methods; 2013 May; 215(2):234-40. PubMed ID: 23537933
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
9. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF).
Rosenling T; Slim CL; Christin C; Coulier L; Shi S; Stoop MP; Bosman J; Suits F; Horvatovich PL; Stockhofe-Zurwieden N; Vreeken R; Hankemeier T; van Gool AJ; Luider TM; Bischoff R
J Proteome Res; 2009 Dec; 8(12):5511-22. PubMed ID: 19845411
[TBL] [Abstract][Full Text] [Related]
10. Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
Le Bastard N; Martin JJ; Vanmechelen E; Vanderstichele H; De Deyn PP; Engelborghs S
Neurobiol Aging; 2010 Nov; 31(11):1867-76. PubMed ID: 19150153
[TBL] [Abstract][Full Text] [Related]
11. Preanalytical factors affecting the stability of matrix metalloproteinase-2 concentrations in cerebrospinal fluid.
Sulik A; Wojtkowska M; Oldak E
Clin Chim Acta; 2008 Jun; 392(1-2):73-5. PubMed ID: 18373981
[TBL] [Abstract][Full Text] [Related]
12. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
13. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.
Wiltfang J; Esselmann H; Bibl M; Hüll M; Hampel H; Kessler H; Frölich L; Schröder J; Peters O; Jessen F; Luckhaus C; Perneczky R; Jahn H; Fiszer M; Maler JM; Zimmermann R; Bruckmoser R; Kornhuber J; Lewczuk P
J Neurochem; 2007 May; 101(4):1053-9. PubMed ID: 17254013
[TBL] [Abstract][Full Text] [Related]
14. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.
Schoonenboom NS; Mulder C; Vanderstichele H; Van Elk EJ; Kok A; Van Kamp GJ; Scheltens P; Blankenstein MA
Clin Chem; 2005 Jan; 51(1):189-95. PubMed ID: 15539465
[TBL] [Abstract][Full Text] [Related]
15. Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation?
Sancesario GM; Esposito Z; Nuccetelli M; Bernardini S; Sorge R; Martorana A; Federici G; Bernardi G; Sancesario G
Exp Neurol; 2010 Jun; 223(2):371-6. PubMed ID: 19664624
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
Clark CM; Xie S; Chittams J; Ewbank D; Peskind E; Galasko D; Morris JC; McKeel DW; Farlow M; Weitlauf SL; Quinn J; Kaye J; Knopman D; Arai H; Doody RS; DeCarli C; Leight S; Lee VM; Trojanowski JQ
Arch Neurol; 2003 Dec; 60(12):1696-702. PubMed ID: 14676043
[TBL] [Abstract][Full Text] [Related]
18. Neurochemical dementia diagnostics: State of the art and research perspectives.
Lewczuk P; Wiltfang J
Proteomics; 2008 Mar; 8(6):1292-301. PubMed ID: 18271068
[TBL] [Abstract][Full Text] [Related]
19. Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid.
Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Touchon J; Perret-Liaudet A; Lehmann S
Brain Res; 2010 Oct; 1357():175-83. PubMed ID: 20713025
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.
Engelborghs S; De Vreese K; Van de Casteele T; Vanderstichele H; Van Everbroeck B; Cras P; Martin JJ; Vanmechelen E; De Deyn PP
Neurobiol Aging; 2008 Aug; 29(8):1143-59. PubMed ID: 17428581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
